

The exercise period for warrants series TO 2 in Amniotics begins today

The exercise period for warrants series TO 2 (the “Warrants”) that were issued in conjunction with Amniotics AB’s (“Amniotics” or the “Company”) rights issue of units which was announced on December 20, 2022 (the “Rights Issue”) begins today, June 5, 2023.

Terms for the Warrants in brief:

- The exercise price has been set to SEK 0.06 per share.
- The exercise price has been defined as seventy (70) per cent of the volume-weighted average price of the Company’s share during the period May 17 – May 31, 2023. The volume-weighted average price for the Company’s share during the period amounted to approximately SEK 0.085.
- The exercise period runs from June 5 – 19, 2023.
- Upon full exercise of all Warrants, a maximum of 101,217,880 shares may be added. If the Warrants are fully exercised, the Company will receive approximately 6.0 MSEK before issue costs.
- Upon full exercise of all Warrants, the number of shares in Amniotics will increase with 101,217,880 shares to 218,502,090 shares and the share capital will increase with SEK 5,474,787.970577 to SEK 11,818,589.896152.
- The announcement of the outcome is planned to: June 21, 2023.

In total, Amniotics issued 101,217,880 units in the Rights Issue, each consisting of one (1) share and one (1) Warrant. The exercise period of the Warrants will run from today, June 5, 2023 until June 19, 2023. One (1) Warrant entitle the right to subscribe for one (1) new share in the Company at an exercise price corresponding to seventy (70) per cent of the volume-weighted average price of the Company’s share during the period from and including May 17, 2023 to and including May 31, 2023, however, not less than SEK 0.055 (corresponding to the approximate quota-value of the share) and not higher than SEK 0.5 per share. The volume-weighted average price of the Company’s share during the period amounted to approximately SEK 0.085. Therefore, the exercise price has been set to SEK 0.06 per share.

In the event of full exercise of all Warrants, the Company will receive approximately 6 MSEK before issue costs. In order for the Warrants not to expire and lose their value, they must be actively sold by June 15, 2023 at the latest or alternatively exercised by June 19, 2023.

In the event of full exercise of all Warrants for subscription of shares, the Company will raise approximately 6 MSEK before issue costs.

Note that Warrants that have not been actively sold by June 15, 2023 at the latest or alternatively exercised by June 19, 2023 will expire and lose their value.

Exercise of Warrants

Trustee-registered Warrants

If the warrant holder holds Warrants in a deposit account, in an investment savings account or endowment insurance (trustee-registered holdings), subscription and payment will take place with the trustee, which will provide further instructions on how to exercise the Warrants. The warrant holder should contact their trustee well in advance for further instructions regarding exercising of the Warrants.

Directly registered Warrants (securities account)

Registration is done through a registration form available on the websites of Vator Securities AB www.vatorsecurities.se and Amniotics www.amniotics.com. Payment is made in accordance with the instructions on the registration form. Both the registration form and payment must be submitted to Vator Securities AB by 3:00 p.m. CEST on June 19, 2023 at the latest.

Advisors

Vator Securities AB acts as financial advisor and issuer agent and Setterwalls Advokatbyrå AB acts as legal advisor to Amniotics in connection with the Rights Issue.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Amniotics. Invitation to the persons concerned to subscribe for units consisting of shares and Warrants in Amniotics has only taken place through the prospectus that Amniotics published on February 17, 2023.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.

Learn more at www.amniotics.com.

Attachments

The exercise period for warrants series TO 2 in Amniotics begins today